Compare iShares Silver Trust (SLV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Viatris Inc — how do they compare? iShares Silver Trust trades at $53.24, while Viatris Inc trades at $16.99 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while iShares Silver Trust pays none, and Viatris Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| SLV | VTRS | |
|---|---|---|
52-Week High | $105.57 | $17.39 |
52-Week Low | $33.32 | $8.74 |
Market Cap | — | $19.79B |
Sector | — | Health |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV, the iShares Silver Trust ETF, trades at $50.98 with a slight 0.39% daily gain. The technical outlook is bearish, with moving averages signaling strong selling pressure and oscillators neutral. Recent news highlights silver's dual role as a monetary and industrial metal, with supply deficits and geopolitical tensions influencing prices. Financial ratios are not applicable as SLV is a commodity trust tracking silver prices, not a company with earnings.
The outlook for SLV hinges on silver's price trajectory, supported by industrial demand and supply constraints but pressured by Fed policy and dollar strength. Risks include volatility from macroeconomic shifts and competition from other silver ETFs like SIVR. Analyst sentiment is mixed, with silver's performance lagging gold year-to-date, yet long-term demand drivers remain intact.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
